MILNACIPRAN HYDROCHLORIDE

MILNACIPRAN HYDROCHLORIDE 구조식 이미지
카스 번호:
92623-85-3
상품명:
MILNACIPRAN HYDROCHLORIDE
동의어(영문):
IXEL;TN-912;F 2207;Milborn;Milnace;TOLEDOMIN;MILNACIPRAN;MIDALCIPRAN;Minapulen D10;MILNACIPRAN HCL
CBNumber:
CB7423244
분자식:
C15H22N2O
포뮬러 무게:
246.35
MOL 파일:
92623-85-3.mol

MILNACIPRAN HYDROCHLORIDE 속성

끓는 점
393.0±21.0 °C(Predicted)
밀도
1.077±0.06 g/cm3(Predicted)
저장 조건
2-8°C
용해도
H2O: 19 mg/mL
물리적 상태
고체
물리적 상태
단단한 모양
산도 계수 (pKa)
10.36±0.29(Predicted)
색상
하얀색
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xn
위험 카페고리 넘버 22
유엔번호(UN No.) UN 2811 6.1/PG 3
WGK 독일 3
RTECS 번호 GZ1014010
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 피부에 자극을 일으킴 피부부식성 또는 자극성물질 구분 2 경고 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 눈에 심한 자극을 일으킴 심한 눈 손상 또는 자극성 물질 구분 2A 경고 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 호흡 자극성을 일으킬 수 있음 특정 표적장기 독성 - 1회 노출;호흡기계 자극 구분 3 경고 GHS hazard pictograms
예방조치문구:
P261 분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P305+P351+P338 눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

MILNACIPRAN HYDROCHLORIDE C화학적 특성, 용도, 생산

개요

Ixel was launched in France as an antidepressant. There are several synthetic routes, the shortest of which is five steps using benzyl cyanide as the starting material. It is a specific serotonin and noradrenaline reuptake inhibitor (SNRI). This dual mechanism of action makes it superior to selective serotonin reuptake inhibitors (SSRI) like fluoxetine and fluvoxamine. Ixel has no significant effect on postsynaptic receptors, very limited effect on cardiac function, and no quinidine-like arrhythmal effects. It has a good side effect profile with lower incidence of anticholinergic-like side effects, less sedation due to histamine H1-receptor binding, and a lack of α1- adrenoceptor antagonism. Ixel has a short half-life (7 hr) with no active metabolites. It is not metabolized by CYP450 therefore drug interaction is unlikely. It is superior in the treatment of serious depression with no need to titrate drug dose.

Mechanism of action

Milnacipran selectively inhibits the reuptake of 5-HT (selectivity ratio, 9) at the presynaptic membrane site, thus increasing the concentration of 5-HT in the synaptic cleft. Although milnacipran is not a TCA, its mechanism of action is similar to that of imipramine, and its binding and reuptake inhibition profile more closely resembles that of the TCAs. Milnacipran has weak affinity for adrenergic, muscarinic, and H1 receptors and, therefore, is expected to be devoid of the prominent side effects observed for the TCAs. In clinical studies, milnacipran showed antidepressant efficacy similar to that of TCAs and SSRIs.

Pharmacokinetics

In humans, milnacipran distinguishes itself from many other antidepressants by its simple pharmacokinetics. It is rapidly absorbed, with a high oral bioavailability, and it exhibits linear pharmacokinetics over a dose range of 25 to 200 mg/day. It circulates in the blood and distributes in the body principally as unmetabolized drug. Steady-state plasma levels are reached within 32 to 48 hours after twice-daily oral administration, and its metabolism does not involve the CYP enzyme system. Approximately 50% of the dose is excreted in urine as unmetabolized drug, and another 14% is excreted as its N-glucuronide conjugate. The remaining eliminated drug is composed of conjugated Phase I inactive metabolites. Because the unmetabolized drug is the only compound responsible for the activity of milnacipran, no dosage adjustment is needed in patients presenting liver impairment.

Clinical Use

(±)-Milnacipran is the ci s-aminomethyl derivative of phenylcyclopropanecarboxamide that acts by inhibiting both NE and 5-HT reuptake. It is structurally different from the other NSRIs and currently is only available in Europe as a racemic mixture, with both enantiomers exhibiting antidepressant activity. Substituting the aminomethyl group of milnacipran with an aminopropyl gives a milnacipran homologue that exhibits antidepressant activity as a potent N-methyl-D-aspartate (NMDA) receptor antagonist. A glutamate hypothesis is being investigated as an alternative mechanism of depression.

부작용

Milnacipran has proven to be a very safe drug, with an adverse-event profile clearly superior to that of TCAs and, to a certain extent, that of SSRIs. Only approximately 10% of patients experience side effects, and only dysuria occurred more frequently (2%) with milnacipran than with TCAs or SSRIs. Milnacipran therefore appears to be an antidepressant with a very favorable benefit:risk ratio, although with a slower onset of action than the TCAs.

MILNACIPRAN HYDROCHLORIDE 준비 용품 및 원자재

원자재

준비 용품


MILNACIPRAN HYDROCHLORIDE 공급 업체

글로벌( 90)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21691 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3620 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
Dayang Chem (Hangzhou) Co.,Ltd.
571-88938639 +8617705817739
info@dycnchem.com CHINA 52867 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10523 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418684 +8618949823763
sales@tnjchem.com China 25363 58
ZHEJIANG JIUZHOU CHEM CO., LTD
+86-0576225566889 +86-13454675544
admin@jiuzhou-chem.com;jamie@jiuzhou-chem.com;alice@jiuzhou-chem.com China 20000 58
Hebei Miaoyin Technology Co.,Ltd
+86-17367732028 +86-17367732028
kathy@hbyinsheng.com China 3582 58
LEAPCHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 43348 58
Amadis Chemical Company Limited
571-89925085
sales@amadischem.com China 131981 58

MILNACIPRAN HYDROCHLORIDE 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved